57 related articles for article (PubMed ID: 6855993)
1. Tamoxifen and prolactin secretion in postmenopausal women with advanced breast cancer.
van der Geest S; Sluiter WJ; Doorenbos H; Reitsma WD
Neth J Med; 1983; 26(4):99-103. PubMed ID: 6855993
[No Abstract] [Full Text] [Related]
2. The effect of tamoxifen and stilboestrol on plasma hormone levels in postmenopausal women with advanced breast cancer.
McFadyen IJ; Raab G; Forrest AP; Langlands AO; Stewart HJ; Roberts MM; Hamilton T; Golder MP; Groom GV; Griffiths K
Clin Oncol; 1979 Sep; 5(3):251-6. PubMed ID: 387323
[No Abstract] [Full Text] [Related]
3. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Mouridsen H; Chaudri-Ross HA
Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status.
Ilanchezhian S; Thangaraju M; Sachdanandam P
Cancer Biochem Biophys; 1995 Nov; 15(2):83-90. PubMed ID: 8590439
[TBL] [Abstract][Full Text] [Related]
5. Effect of tamoxifen treatment on estrogen metabolism in postmenopausal women with advanced breast cancer.
Levin J; Markham MJ; Greenwald ES; O'Connor JF; Zumoff B; Fukushima DK
Anticancer Res; 1982; 2(6):377-80. PubMed ID: 7168557
[TBL] [Abstract][Full Text] [Related]
6. The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer.
Stewart HJ; Forrest AP; Gunn JM; Hamilton T; Langlands AO; McFadyen IJ; Roberts MM
Eur J Cancer (1965); 1980; Suppl 1():83-8. PubMed ID: 7032945
[No Abstract] [Full Text] [Related]
7. CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
Mouridsen HT; Palshof T; Engelsman E; Sylvester R
Eur J Cancer (1965); 1980; Suppl 1():119-23. PubMed ID: 7032921
[No Abstract] [Full Text] [Related]
8. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
9. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women.
Stamatelopoulos KS; Lekakis JP; Poulakaki NA; Papamichael CM; Venetsanou K; Aznaouridis K; Protogerou AD; Papaioannou TG; Kumar S; Stamatelopoulos SF
Am Heart J; 2004 Jun; 147(6):1093-9. PubMed ID: 15199361
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen therapy in breast cancer control worldwide.
Love RR; Koroltchouk V
Bull World Health Organ; 1993; 71(6):795-803. PubMed ID: 8313498
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.
Mouridsen HT; Salimtschik M; Dombernowsky P; Gelshoj K; Palshof T; Rorth M; Daehnfeldt JL; Rose C
Eur J Cancer (1965); 1980; Suppl 1():107-10. PubMed ID: 7032918
[No Abstract] [Full Text] [Related]
14. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
15. Effects of metoclopramide and TRH on prolactin release in women with breast cancer.
Schieppati G; Monza GC; Neri V; Sali L; Navassa G; Picozzi R; Tarolo GL; Lampertico M
J Nucl Med Allied Sci; 1983; 27(3):225-30. PubMed ID: 6420524
[No Abstract] [Full Text] [Related]
16. [Effects of the treatment with an antiestrogen(tamoxifen) and levodopa on the secretion of prolactin in patients affected by breast cancer].
Di Benedetto G; Gallamini A; Nizzo MC; Costa M; Indiveri F
Boll Soc Ital Biol Sper; 1976 Oct; 52(19):1572-5. PubMed ID: 1024568
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and breast cancer--from palliation to prevention.
Rich SE
Cancer Nurs; 1993 Oct; 16(5):341-6. PubMed ID: 7505194
[TBL] [Abstract][Full Text] [Related]
18. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen.
Lahti E; Blanco G; Kauppila A; Apaja-Sarkkinen M; Taskinen PJ; Laatikainen T
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):660-4. PubMed ID: 8469450
[TBL] [Abstract][Full Text] [Related]
19. Sensory perceptions of women receiving tamoxifen for breast cancer.
McDaniel RW; Rhodes VA; Nelson RA; Hanson BM
Cancer Nurs; 1995 Jun; 18(3):215-21. PubMed ID: 7600553
[TBL] [Abstract][Full Text] [Related]
20. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity?
Cohen I; Beyth Y; Tepper R; Figer A; Shapira J; Cordoba M; Yigael D; Altaras MM
Gynecol Oncol; 1995 Jul; 58(1):86-91. PubMed ID: 7789896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
